The Vox Markets Podcast / Jeremy Skillington of Poolbeg Pharma discusses their exclusive in-licence of RNA-based immunotherapy asset

View our embed guidelines

Sorry, your browser isn't supported.

We recommend upgrading to the latest Chrome, Firefox, Safari, or Edge.

You can visit our support center if you're having problems.